

Novel Targeted Radiopharmaceuticals for Diagnosis and Therapy

Guest Editors:

Dr. Kristina Djanashvili

Department of Biotechnology,
Delft University of Technology,
Delft, The Netherlands

Dr. Sara Lacerda

Center of Molecular Biophysics,
CNRS, Orléans, France

Deadline for manuscript
submissions:


31 July 2024

Message from the Guest Editors

The development of new radiopharmaceuticals designed for the diagnosis and therapy of various diseases is a rapidly growing field of research towards precision health solutions. As a result, the remarkable clinical potential of radiolabeled probes is currently receiving increased attention from clinicians and pharmaceutical companies. However, a challenging aspect in the acceptance of the novel probes remains the multidisciplinary nature of the research that requires expertise in (radio)chemistry, radiobiology, medicine, and medical physics, which consequently necessitates collaborative approaches.

This Special Issue of *Molecules* is open for articles (reviews, research papers and communications) with a focus on strategies for the synthesis and radiolabeling of novel targeted radiopharmaceuticals as well as in vitro and in vivo evaluations of their diagnostic and therapeutic performances. Subjects might include but are not limited to designs of new chelators for various radiometals, targeting vectors and linkers for their conjugation, or the introduction of radiohalogens into the structure of biomolecules.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Chemistry, Multidisciplinary*) / CiteScore - Q1 (*Chemistry (miscellaneous)*)

Contact Us

Molecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](https://twitter.com/X@Molecules_MDPI)